Tadokoro S,
Otani N, Young A, Ozasa K, Noma N. Therapeutic Efficacy of Mirogabalin in
managing Trigeminal Neuralgia. J Clin Exp Dent. 2024;16(5):e652-5.
doi:10.4317/jced.61552
https://doi.org/10.4317/jced.61552
____
References
|
1.
International Classification of Orofacial Pain, 1st edition (ICOP).
Cephalalgia. 2020;40:129-221. |
|
|
|
|
|
2.
Deeks, E.D. Mirogabalin: First Global Approval. Drugs. 2019;79:463-68. |
|
|
|
|
|
3.
Kato, J.; Matsui, N.; Kakehi, Y. Murayama, E.; Ohwada, S.; Sugihara, M.
Mirogabalin for the management of postherpetic neuralgia. A randomized,
double-blind, placebo-controlled phase 3 study in Asian patients. Pain.
2019;160:1175-85. |
|
|
|
|
|
4.
Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment
of diabetic peripheral neuropathic pain: a randomized, double-blind,
placebo-controlled phase III study in Asian patients. J Diabetes Investig.
2019;10:1299-306. |
|
|
|
|
|
5.
Zajączkowska R, Mika J, Leppert W, Kocot-Kępska M, Malec-Milewska M,
Wordliczek J. Mirogabalin - a novel selective ligand for the α2δ calcium
channel subunit. Pharmaceuticals (Basel). 2021;14:112. |
|
|
|
|
|
6.
Cheshire WP Jr. Defining the role for gabapentin in the treatment of
trigeminal neuralgia: a retrospective study. J Pain. 2002;3:137-42. |
|
|
|
|
|
7.
Obermann M, Yoon MS, Sensen K, Maschke M, Diener HC, Katsarava Z. Efficacy of
pregabalin in the treatment of trigeminal neuralgia. Cephalalgia.
2008;28:174-81. |
|